Legal & General Group Plc Lowers Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Legal & General Group Plc cut its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 6.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 602,858 shares of the company's stock after selling 38,584 shares during the period. Legal & General Group Plc owned 0.08% of Roivant Sciences worth $7,132,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Barclays PLC lifted its holdings in shares of Roivant Sciences by 19.7% during the third quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after purchasing an additional 75,609 shares during the last quarter. Virtu Financial LLC bought a new stake in Roivant Sciences in the third quarter worth $207,000. Te Ahumairangi Investment Management Ltd grew its stake in shares of Roivant Sciences by 19.9% in the third quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company's stock worth $2,313,000 after acquiring an additional 33,467 shares during the last quarter. Tyro Capital Management LLC grew its position in Roivant Sciences by 0.6% during the 3rd quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company's stock valued at $20,252,000 after purchasing an additional 10,649 shares during the last quarter. Finally, Retirement Systems of Alabama raised its holdings in Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock worth $6,116,000 after buying an additional 112,286 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Insider Activity

In other Roivant Sciences news, COO Eric Venker sold 218,041 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22. Following the transaction, the chief operating officer now owns 896,869 shares of the company's stock, valued at $9,345,374.98. This represents a 19.56 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,395,541 shares of company stock worth $14,922,538 over the last ninety days. Corporate insiders own 7.90% of the company's stock.

Roivant Sciences Stock Performance

Shares of ROIV stock traded up $0.12 on Thursday, reaching $10.86. The stock had a trading volume of 910,764 shares, compared to its average volume of 5,411,250. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The stock has a market cap of $7.75 billion, a P/E ratio of -72.43 and a beta of 1.25. The company has a 50 day simple moving average of $10.33 and a 200 day simple moving average of $11.15.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

ROIV has been the subject of a number of research analyst reports. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Monday.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.